Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Daiichi Sankyo Company, Limited
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Created shared value with stakeholders === * Patients: Contributing to patents through "Patient Centric Mindset" * Shareholders: Balanced investment for growth and shareholder returns * Society: Environment load reduction across the value chain, and actions against pandemic risks * Employees: Create one DS culture through fostering our core behaviours The first 2 strategic pillars are outlined below in "'''Products'''". Daiichi Sankyo has several emerging candidates for new growth following 3ADCs. One such driver is the development of DS-7300 which has shown promising durable response in patients with several types of advanced cancer, this is a "first-in-class" B7-H3 directed DXd antibody drug conjugate (ADC), which continues to show promising durable tumour response in patients with several types of heavily pre-treated cancers, including lung, prostate or oesophageal cancer. In 2022, the drug was found to have a response rate of 32%, with 32 responses in 118 patients with various solid tumours.<ref>https://www.daiichisankyo.com/files/news/pressrelease/pdf/202209/20220910_E.pdf</ref> DS-6000, a CDH6-directed ADC, has also entered development. This drug targets patients with advanced ovarian cancer or renal cell carcinoma. Patients with these diseases have very low survival rates, at 30% and 15% respectively. CDH6 is overexpressed significantly in both of these cancers. Preliminary efficacy results in 20 evaluable patients included six partial responses (50% reduction in tumour size), 12 patients reported with stable disease (Neither increases in size >20%, nor decrease >30%) in platinum-resistant ovarian cancer. Eight CA-125<ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764643/#:~:text=CA125%20is%20the%20gold%20standard,progression%20in%20ovarian%20cancer%20patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764643/#:~:text=CA125%20is%20the%20gold%20standard,progression%20in%20ovarian%20cancer%20patients.]</ref> (gold standard ovarian cancer marker) responses observed in 17 evaluable patients with ovarian cancer.<ref>https://daiichisankyo.us/press-releases/-/article/ds-6000-suggests-early-clinical-activity-in-patients-with-advanced-ovarian-cancer-or-renal-cell-carcinoma</ref> The company is also taking steps to create shared value with stakeholders via several measures, such as increasing dividend yield per share from 27 JPY to 30 JPY in FY2022, and joining RE100, a global initiative aiming to use 100% renewable energy for electricity consumed in business activities<ref>https://www.daiichisankyo.com/files/investors/library/quarterly_result/2022/5thMTP_update_2304.pdf</ref> As of 2023 Apr, the revenue and revenue in oncology targets for 2025 have been '''vastly exceeded''', with current values at 2.0 Tr JPY and >900 Bn JPY, respectively<ref>https://www.daiichisankyo.com/files/investors/library/quarterly_result/2022/5thMTP_update_2304.pdf</ref>. However, the USD/JPY exchange ratio needs to be taken into account. The exchange rate in 2021 being 1 USD = 105 JPY, and the exchange rate at the time of 2023 Apr being 1 USD = 130 JPY, and as of July 2023, 1 USD = 138 JPY. This indicates that an increase in revenue may be misleading depending upon how much of Daiichi Sankyo's revenue comes from overseas. As of 2022, overseas sales made up 58% of total sales.<ref>https://www.daiichisankyo.com/investors/financial_highlights/</ref>
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)